InfaCare raises $28 million for neonatal drug development
This article was originally published in Scrip
InfaCare Pharmaceuticals has secured $28 million to advance the development its Stanate (stannsoporfin), its product for neonatal hyperbilirubinaemia. The compound is expected to enter a Phase III trial in 2009 and is the only drug in development to prevent bilirubin from reaching toxic levels in haemolysing neonates, the company says. The product inhibits haem oxygenase, an enzyme involved in bilirubin formation, and is designed to reduce the neurological risks associated with uncontrolled hyperbilirubinaemia. The series B round was led by HealthCare Ventures and Longitude Capital, which will each have a partner on InfaCare's board.
You may also be interested in...
AB Science has closed its IPO at just half of the value of its initial expectations. The gross proceeds of the French firm's offer were €27.5 million, compared with the €55.5 million it anticipated when it filed for the offering on 8 April. Of the total, the company secured $16.5 million from the sale of newly issued shares; the remaining €11 million went to selling shareholders.
Amgen's sales rebounded in the first quarter rising 9% to $3.6 billion after a disappointing end to last year. However, the introduction of new legislation for US healthcare has weighed on its forecast for the year, as it has done for many of its competitors.
Actelion's total revenues leapt up by 24% to CHF502 million ($467 million) during the first quarter due to stronger demand for its pharmaceuticals. The firm's net income rose by 30% to CHF133 million, while its diluted EPS increased from CHF0.83 in the first quarter last year to CHF1.09.